Progyny is demonstrating structural margin expansion, with gross margin improving to 25.5% in Q2 2026 from 23.7% a year earlier, while operating leverage drives operating margin to 11.4%. However, revenue growth decelerated to 5.3% year-over-year due to the lo...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.36+7.5% vs $0.33 | $351M+0.4% vs $349M |
Q2 2026 May 7, 2026 | $0.30+17.2% vs $0.26 | $329M+0.6% vs $326M |
Q1 2026 Feb 26, 2026 | $0.15+2.0% vs $0.15 | $318M+3.6% vs $307M |
Q4 2025 Nov 6, 2025 | $0.16-59.0% vs $0.39 | $313M+4.7% vs $299M |
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
The mean of analysts' price targets for Progyny (PGNY) points to a 25.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.
Benchmark PGNY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Progyny, Inc. (PGNY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.83 | $2.02B | 39.74 | 10.4% | 4.54% | 12.48% | — | |
| $28.39 | $6.33B | 55.67 | 59% | -5.51% | -30.03% | — | |
| $12.08 | $4.69B | 604.00 | 13.85% | 3.19% | 3.39% | — | |
| $3.32 | $1.15B | 38.92 | 0.57% | 2.07% | 2.61% | — | |
| $85.86 | $109.55B | 61.77 | 7.85% | 1.18% | 6.41% | — | |
| $268.27 | $70.97B | 12.10 | 11.26% | 2.27% | 15.16% | — |
Progyny, Inc. (PGNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Progyny, Inc. (PGNY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
May 27, 2026·SEC
May 26, 2026·SEC
Get notified when PGNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Progyny, Inc. (PGNY) stock FAQ — growth, dividends, profitability & financials explained
Progyny, Inc. (PGNY) reported $1.31B in revenue for fiscal year 2025. This represents a 2598% increase from $48.6M in 2017.
Progyny, Inc. (PGNY) grew revenue by 10.4% over the past year. This is steady growth.
Yes, Progyny, Inc. (PGNY) is profitable, generating $78.6M in net income for fiscal year 2025 (4.5% net margin).
Progyny, Inc. (PGNY) has a return on equity (ROE) of 12.5%. This is reasonable for most industries.
Progyny, Inc. (PGNY) generated $218.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
